Search results
Oral P2Y12 Inhibitors and Drug Interactions
Author(s):
Elisabetta Bigagli
,
Jacopo Angelini
,
Alessandro Mugelli
,
et al
Added:
9 months ago
Review Article
Author(s):
Tobias Geisler
Added:
1 year ago
Author(s):
Ton Duy Mai
,
Tri Huynh Quang Ho
,
Sy Van Hoang
,
et al
Added:
10 months ago
Added:
1 week ago
Source:
Radcliffe Cardiology
Written by Mirjam Boros, Radcliffe CardiologyA new oral proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor, enlicitide, has demonstrated a significant reduction in low-density lipoprotein cholesterol (LDL-C) levels in patients with or at risk of atherosclerotic cardiovascular disease (ASCVD), according to results from the CORALreef Lipids trial.¹Mechanism of ActionEnlicitide is an…
View more
AHA 25: The OCEAN Trial
Author(s):
Atul Verma
Added:
3 months ago
Video
Author(s):
Francesco Pelliccia
Added:
10 months ago
SCAI 2025 - Insights from antiplatelet therapy after transcatheter aortic valve replacement (TAVR) show patients who received single antiplatelet treatment had significantly lower rates of overall six-month mortality, CV death and non-CV death compared to those treated with double antiplatelet treatment.Dr Francesco Pelliccia (Sapienza University of Rome, Rome, IT) joins us to discuss insights…
View more
Author(s):
Gi-Byoung Nam
,
Min Soo Cho
Added:
1 year ago
ESC Congress 2024 — Edoxaban monotherapy significantly improves outcomes in high-risk patients with CAD and atrial fibrillation.Investigators, Dr Gi-Byoung Nam (Ulsan University Hospital, Ulsan, SK) and Dr Min Soo Cho (Asan Medical Center, Seoul, SK) join us to discuss the key findings from the EPIC-CAD trial (NCT03718559).This Korean multi-centre, open-labelled, randomised controlled study…
View more
Prioritising Risk in CAD: A Patient-First Discussion
Video Series
Author(s):
Christie Ballantyne
Added:
3 months ago
AHA Scientific Sessions 2025 - Dr Christie Ballantyne (Baylor College of Medicine, Houston, TX, US) discusses findings from the CORALreef HeFH trial, examining the efficacy and safety of enlicitide decanoate, an oral PCSK9 inhibitor, in adults with heterozygous familial hypercholesterolemia.This Phase 3, randomized, double-blind, placebo-controlled study evaluated 303 participants with…
View more
Anticoagulant Use in Older Adults
Author(s):
Monika Bhandari
,
Akshyaya Pradhan
,
Pravesh Vishwakarma
,
et al
Added:
1 year ago
Review Article